Skip to content
  1. Home
  2. News
  3. Reata Pharmaceuticals Prices Class A Common Stock Offering

Reata Pharmaceuticals Prices Class A Common Stock Offering

Deals & Cases
December 1, 2020

Vinson & Elkins advised Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, in its public offering of 2,000,000 shares of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of $281.7 million.

The offering priced on December 1, 2020 and is expected to close on or about December 4, 2020.

Reata develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.

The V&E corporate team was led by partner Robert Kimball with assistance from senior associate Katherine Frank and associates Grace-Ann Duquette and Joseph Steuert. Advising on tax matters were partner Wendy Salinas and associate Liz Snyder.

About Vinson & Elkins
For more than a century, Vinson & Elkins has provided outstanding client service across important industries that drive the global economy. Built on a strong culture of collaboration across 12 offices worldwide, V&E lawyers are committed to excellence, offering clients decades of legal experience in handling transactions, investments, projects and disputes across the globe. Learn more by visiting www.velaw.com or follow us on Twitter @VinsonandElkins or connect with us on LinkedIn.

For more information, please speak with our media contacts.

Key Contacts